PharmacyCodes



Pacerone en es it fr

Pacerone Brand names, Pacerone Analogs

Pacerone Brand Names Mixture

  • No information avaliable

Pacerone Chemical_Formula

C25H29I2NO3

Pacerone RX_link

http://www.rxlist.com/cgi/generic/amiodarone.htm

Pacerone fda sheet

Pacerone FDA

Pacerone msds (material safety sheet)

Pacerone MSDS

Pacerone Synthesis Reference

No information avaliable

Pacerone Molecular Weight

645.312 g/mol

Pacerone Melting Point

No information avaliable

Pacerone H2O Solubility

Low

Pacerone State

Solid

Pacerone LogP

7.706

Pacerone Dosage Forms

Liquid; Solution; Tablet (200 mg and 400 mg)

Pacerone Indication

Intravenously, for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy. Orally, for the treatment of life-threatening recurrent ventricular arrhythmias such as recurrent ventricular fibrillation and recurrent hemodynamically unstable ventricular tachycardia.

Pacerone Pharmacology

Amiodarone belongs to a class of drugs called Vaughan-Williams Class III antiarrhythmic agents. It is used in the treatment of a wide range of cardiac tachyarhthmias, including both ventricular and supraventricular (atrial) arrhythmias. After intravenous administration in man, amiodarone relaxes vascular smooth muscle, reduces peripheral vascular resistance (afterload), and slightly increases cardiac index. Amiodarone prolongs phase 3 of the cardiac action potential. It has numerous other effects however, including actions that are similar to those of antiarrhythmic classes Ia, II, and IV. Amiodarone shows beta blocker-like and calcium channel blocker-like actions on the SA and AV nodes, increases the refractory period via sodium- and potassium-channel effects, and slows intra-cardiac conduction of the cardiac action potential, via sodium-channel effects.

Pacerone Absorption

Slow and variable (about 20 to 55% of an oral dose is absorbed).

Pacerone side effects and Toxicity

Intravenous, mouse: LD50 = 178 mg/kg. Some side effects have a significant mortality rate: specifically, hepatitis, exacerbation of asthma and congestive failure, and pneumonitis.

Pacerone Patient Information

No information avaliable

Pacerone Organisms Affected

Humans and other mammals